Biosimilar Notice Rule Isn't Absolute, Apotex Tells Fed. Circ.

By Jimmy Hoover (April 4, 2016, 5:10 PM EDT) -- Apotex urged a Federal Circuit panel to reverse a lower court's finding that biosimilar makers must always give 180-day advance notice of sales to brand-name rivals, arguing in a dispute over a proposed biosimilar for Amgen blockbuster Neulasta that the notice requirement only applies when they don't first exchange intellectual property information....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.

A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!